MedPath

北京布霖生物科技有限公司

Ownership
-
Established
2021-08-24
Employees
-
Market Cap
-
Website
www.bulinshengwu.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

13

NMPA:13

Drug Approvals

Carboplatin Injection

Product Name
卡铂注射液
Approval Number
国药准字H20253912
Approval Date
Apr 15, 2025
NMPA

Carboplatin Injection

Product Name
卡铂注射液
Approval Number
国药准字H20253911
Approval Date
Apr 15, 2025
NMPA

Potassium Chloride Injection

Product Name
氯化钾注射液
Approval Number
国药准字H20253478
Approval Date
Feb 25, 2025
NMPA

Sodium Glycerophosphate Injection

Product Name
甘油磷酸钠注射液
Approval Number
国药准字H20253285
Approval Date
Jan 24, 2025
NMPA

Adenosine Injection

Product Name
腺苷注射液
Approval Number
国药准字H20249461
Approval Date
Dec 1, 2024
NMPA

Betamethasone Sodium Phosphate Injection

Product Name
倍他米松磷酸钠注射液
Approval Number
国药准字H20244487
Approval Date
Oct 22, 2024
NMPA

Triptorelin Acetate Injection

Product Name
醋酸曲普瑞林注射液
Approval Number
国药准字H20244811
Approval Date
Sep 3, 2024
NMPA

Isosorbide Dinitrate Injection

Product Name
硝酸异山梨酯注射液
Approval Number
国药准字H20244388
Approval Date
Jul 9, 2024
NMPA

Dobutamine Hydrochloride Injection

Product Name
盐酸多巴酚丁胺注射液
Approval Number
国药准字H20243911
Approval Date
Jun 4, 2024
NMPA

Famotidine Injection

Product Name
法莫替丁注射液
Approval Number
国药准字H20243730
Approval Date
May 15, 2024
NMPA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.